Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
October 07 2024 - 12:00AM
UK Regulatory
Galapagos welcomes Oleg Nodelman to its Board of Directors to
support strategic growth
Mechelen, Belgium; October 7, 2024, 07:00
CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced
the appointment by way of co-optation of Oleg Nodelman as
Non-Executive Non-Independent Director to its Board of Directors,
effective October 7, 2024.
Mr. Nodelman replaces Mr. Dan G. Baker who
stepped down on October 6, 2024. The addition of Mr. Nodelman marks
an important step in Galapagos’ ongoing efforts to engage with
shareholders and continue to execute on our Forward,
Faster strategy to accelerate innovation and create near-and
long-term value.
“We are pleased to welcome Oleg Nodelman to the
Galapagos Board,” said Dr. Paul Stoffels, Galapagos’ CEO and Chair
of the Board of Directors1. “His deep expertise in
biotech and shared goals of unlocking further value for Galapagos
will be instrumental in helping us execute our near- and long-term
strategy and deliver superior results for patients, shareholders,
employees, and customers.”
Mr. Nodelman is the Founder and Portfolio
Manager of EcoR1 Capital LLC, a biotech-focused investment advisory
firm which invests in companies at all stages of research and
development. Mr. Nodelman brings a wealth of experience in driving
shareholder value, strategic transformations, and long-term growth
initiatives. With a proven record in investment management –
including business development and capital deployment – and his
deep roots in the biotech and scientific communities, Mr.
Nodelman’s appointment signals Galapagos’ commitment to
accelerating value for all shareholders.
“I am excited to join the Galapagos Board and
work with the management team to realize the Company’s full value
potential,” said Mr. Nodelman. “As one of Galapagos’ largest
shareholders, EcoR1 is committed to the Company’s future
success.”
Mr. Nodelman holds a Bachelor of Science in
Foreign Service with a concentration in Science and Technology from
Georgetown University.
We want to thank Dan for his invaluable
contributions in helping to reset the R&D strategy at Galapagos
and the Board is grateful to him for his leadership as Chair of the
Science and Development Committee of the Company. During his
time at Galapagos, Dan shared his extensive clinical expertise as a
rheumatologist as well as his deep insights in drug development
from his experience at Johnson & Johnson, where he helped
develop REMICADE®, SIMPONI®, and STELARA®. We wish Dan all the best
as he leaves Galapagos to pursue other ventures. Dan will continue
to serve the Company as a scientific advisor.
About Galapagos
We are a biotechnology company with operations in Europe and the
U.S. dedicated to transforming patient outcomes through
life-changing science and innovation for more years of life and
quality of life. Focusing on high unmet medical needs, we synergize
compelling science, technology, and collaborative approaches to
create a deep pipeline of best-in-class small molecules and cell
therapies in oncology and immunology. With capabilities from lab to
patient, including a decentralized cell therapy manufacturing
platform, and the financial strength to invest strategically for
the long-term, we are committed to challenging the status quo and
delivering results for our patients, employees, and shareholders.
Our goal is not just to meet current medical needs but to
anticipate and shape the future of healthcare, ensuring that our
innovations reach those who need them most. For additional
information, please visit www.glpg.com or follow us
on LinkedIn or X.
For further information, please
contact:
Media
inquiries:
Srikant Ramaswami
+1 412 699 0359
media@glpg.com
Marieke Vermeersch
+32 479 490 603
media@glpg.com
Jennifer Wilson
+ 44 7444 896759
media@glpg.com |
Investor
inquiries:
Sofie Van Gijsel
+1 781 296 1143
ir@glpg.com
Sandra Cauwenberghs
+32 495 58 46 63
ir@glpg.com |
Forward-looking statements
This press release may include forward-looking
statements, all of which involve certain risks and
uncertainties. These statements are often, but not always, made
through the use of words or phrases such as “will,”
“long-term,” and “forward,” and any similar
expressions. These statements include, but are not
limited to, statements regarding the appointment of a new
director. Any forward-looking statements in this press release
are based on our management’s current expectations and beliefs and
are not guarantees of future performance. Forward-looking
statements may involve unknown and known risks, uncertainties and
other factors which might cause our actual
results, performance, or achievements to be materially
different from any historic or future results, performance, or
achievements expressed or implied by such statements. These
risks, uncertainties and other factors include, without limitation,
the risk that we may not be able to realize the expected
benefits from the appointment of the new director. A
further list and description of these risks, uncertainties and
other factors can be found in our filings and reports with the
Securities and Exchange Commission (SEC), including in our most
recent annual report on Form 20‐F filed with the SEC, as
supplemented and/or modified by any other filings and reports that
we have made or will make with the SEC in the future. Given
these risks and uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. In addition,
even if our results, performance, or achievements are
consistent with such forward-looking statements, they may not be
predictive of results, performance, or achievements in future
periods. These forward-looking statements speak only as of the date
of publication of this press release. We expressly disclaim
any obligation to update any forward-looking statements in this
press release, unless required by law or regulation.
1 Throughout this press release, ‘Dr.
Paul Stoffels’ should be read as ‘Dr. Paul Stoffels, acting via
Stoffels IMC BV’.
- GLPG Press Release BOD Changes_241007_ENG
Galapagos (TG:GXE)
Historical Stock Chart
From Nov 2024 to Dec 2024
Galapagos (TG:GXE)
Historical Stock Chart
From Dec 2023 to Dec 2024